#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: multiple myeloma
Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients
Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ineligible ...
#VisualAbstract: Belantamab Mafodotin in Combination with Standard-Care Therapies Improved Progression-Free Survival in Patients with Multiple Myeloma Compared to Standard-Therapy Alone
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may ...
Johnson & Johnson and Legend Biotech’s Carvykti shows improved survival in treatment-experienced multiple myeloma patients
As a 2nd line therapy for multiple myeloma, Carvykti can lower the risk of disease progression or death by 59% ...
Daratumumab linked to improved progression-free survival and MRD-negativity in transplant-eligible myeloma patients
1. Daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) as induction and consolidation therapy led to superior progression-free survival ...
#VisualAbstract: Belantamab Mafodotin, Pomalidomide, and Dexamethasone Improve Outcomes in Multiple Myeloma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Minimal Residual Disease negativity after Autologous Hematopoietic Cell Transplantation with lenalidomide maintenance predicts better long-term outcomes in myeloma
1. Achieving Minimal Residual Disease (MRD) negativity at baseline before lenalidomide maintenance, and at one-year post Auto-HCT (AutoHCT) predicts increased ...
Subcutaneous daratumumab with VRd improves progression-free survival in multiple myeloma
1. Adding subcutaneous daratumumab to VRd (bortezomib, lenalidomide, and dexamethasone) induction/consolidation, and lenalidomide maintenance therapy improves progression-free survival in eligible ...
#VisualAbstract: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed ...
#VisualAbstract: Cilta-cel or Standard Care in Lenalidomide Refractory Multiple Myeloma
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...